Mizuho initiated coverage of Kymera Therapeutics (KYMR) with an Outperform rating and $81 price target The company’s lead asset KT-621 is positioned to demonstrate potentially compelling signals of efficacy in atopic dermatitis, the analyst tells investors in a research note. Piper expects the Phase 1b readout in Q4. It projects $2.6B in risk-adjusted 2035 worldwide sales and positive data in Q4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $80 from $60 at Citi
- Nurix Therapeutics price target lowered to $22 from $25 at Wells Fargo
- Kymera Therapeutics: Promising Advancements and Strategic Collaborations Drive Buy Rating
- Kymera Therapeutics participates in a conference call with JPMorgan
- Kymera Therapeutics price target raised to $63 from $53 at Oppenheimer